You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Universal Attenuated Sporozoite Vaccine and Challenge System

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT Sanaria s Plasmodium falciparumPfsporozoiteSPZvaccines development program is receiving global supportTrials of PfSPZ Vaccineradiation attenuated PfSPZor PfSPZ CVacPfSPZ Chemoprophylaxis Vaccineadministered by direct venous inoculationDVIincludingadults to infants were initiated in DecemberTanzaniaU Sor will be initiated in earlyin MaliKenyainfantsGhanaEquatorial GuineaGermany andaddition ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: 102

    DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. IGF OT IGF "ID CAP SYSTEM" PURPOSE TO EXTEND THE PERIOD OF PERFORMANCE FOR THREE ADDITIONAL MONTHS MODIFY CONTRACT CLAUSES IN SECTIONS B F AND G AND MAKE AN ADMINISTRATIVE CHANGE IN PRISM N D

    SBC: ETECT, INC.            Topic: NIDA

    e Tect has created a medication adherence monitoring system called ID Cap consisting of a tag smaller than the size of a postage stamp that can be wrapped around a capsule or attached to a pill When the tagged medication is ingested it activates and sends a signal to a reader worn on the arm The reader relays the signals securely to a remote database enabling accurate medication adherence monit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Novel DFG out inhibitors of Abl-kinases to treat PML

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Inhibikase Therapeutics is a clinical stage biopharmaceutical company that has developed a host targeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalopathy PML PML is a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid s During the ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Protease chain reactions for molecular analysis of cancer markers

    SBC: POTOMAC AFFINITY PROTEIN LLC            Topic: 102

    DESCRIPTION provided by applicant Our objective is to develop a Protease Chain Reaction technology ProCR that will enable ultra sensitive and highly quantitative detection of cancer markers The basic element of a protease chain reaction is a protease inhibitor complex The protease is inactive when bound to the inhibitor but once freed is capable of cleaving the inhibitor and releasing ad ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Software for improved accuracy and rapid tracking of kinematics from dynamic Xray

    SBC: C-MOTION, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Orthopaedic disorders are a leading cause of disability in the U S with arthritis and or spine problems adversely affecting quality of life fo more than of adults While advances in diagnostic imaging have greatly improved our ability to detect structural changes in musculoskeletal tissues they typically reveal little about joint function There is evid ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about in platelet units which is several orders of magnitude greater than that of HIV Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients The American Association of Blood Banks is ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Selective Inhibitors of NaV as Therapeutics for Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 108

    PROJECT SUMMARY This program aims to develop a novel non opioid therapeutic for the treatment of pain that targets a subtype of the human voltage gated Na ion channel NaV Preliminary data indicate that SiteOneandapos s lead drug candidates may be more effective than opioids for treating certain types of pain and lack the side effects associated with opioid analgesics which include nausea ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Phosphodiesterase-4B (PDE4B) Inhibitors for Alzheimer's Disease

    SBC: Tetra Discovery Partners, Inc.            Topic: 101

    Under the parent grantTetra Discovery Partners is developing phosphodiesteraseBPDE Ballosteric inhibitors as a treatment for major depressive disorderUniquelythe Tetra drug will address inflammation as a contributor to depressionThis is a new mechanism of action for an antidepressant drug which should prove complimentary to current therapeuticsThe company estimates thatof patients with depression ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government